SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children. This landmark decision is driving widespread community discussion about its de-risking impact, significant revenue potential, and possible short squeeze, with many speculating on substantial price targets and a potential buyout by a larger pharmaceutical entity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its high-speed, compliance-first Layer 1 infrastructure, which boasts impressive transaction throughput. The community is actively discussing its potential as a "financial plumbing" solution for institutions, especially with its integration of a fiat anchor from Bridge (a Stripe company) now operational. Many view KTA as an undervalued asset for cross-chain settlement and regulated financial flows, positioning it as a compelling complementary play to established crypto and tech giants.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending after federal regulators approved an emergency permit and granted interstate status for its Santa Ynez Pipeline System, shifting regulatory authority from California to federal oversight. This is widely seen as a game-changing event that could enable the company to finally move stored oil and potentially trigger a short squeeze. However, some investors remain cautious about possible state-level legal challenges or the potential for future equity offerings.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is trending amid widespread community accusations of being a "scam" or "rugpull," with many investors expressing deep frustration over its recent performance. Sentiment is heavily bearish, with calls to sell and shift assets to other cryptocurrencies like XRP, though a smaller group sees current price levels as an opportune time for accumulation ahead of a potential rebound.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to promising preliminary Phase 3 open-label data indicating a significant reduction in breast cancer recurrence rates. The community is actively discussing the very high cost-to-borrow rates and a low share float, fueling strong short-squeeze speculation. This is compounded by significant insider buying from the CEO, leading to widespread anticipation of a major partnership or acquisition within the biotech sector.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by positive regulatory developments, strategic divestitures, and key partnerships in wealth management and digital payments. This rally has sparked extensive community discussion, with many celebrating its strong performance and ongoing transformation plan, while others express caution due to its rapid ascent and overbought technical indicators. The positive sentiment is reinforced by strong earnings and analyst upgrades, positioning it as a notable performer within the broader financial sector.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently seeing a surge in conversation and trading volume following reports of significant insider stock purchases, notably by Apple CEO and Nike board member Tim Cook. This move has ignited fervent debate among the community, with many interpreting it as a strong vote of confidence and a potential turning point for the struggling brand, while skeptics question its fundamental impact amidst ongoing performance concerns.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

YEE Crypto is experiencing a surge in attention, driven by a fiercely loyal community actively buying dips and declaring it a generational opportunity within the Ethereum ecosystem. The conversation centers on an unfolding 'prophecy,' strong bullish momentum, and comparisons to legendary meme coins, positioning YEE as a potential catalyst for significant growth.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending following a definitive agreement for acquisition by Sanofi for a notable cash value, which sent the stock surging. The community is actively discussing the offer, with many long-term shareholders expressing mixed sentiments: celebrating significant gains while a vocal segment believes the valuation is too low given the company's Hepatitis B vaccine, Heplisav-B, and promising shingles vaccine candidate.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a top trending stock after securing FDA approval for its oral Wegovy pill, marking a significant milestone as the first GLP-1 oral therapy for weight management. The community is buzzing with excitement over the convenience of a pill versus injections, anticipating a massive expansion of the obesity market and a competitive edge against rivals. Investors are looking for a substantial re-rating of the stock, believing this approval signals a new era of growth and market leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Squarepoint Ops LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS

Squarepoint Ops LLC lifted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 163.7% in the second quarter, according to its most recent filing with the SEC. The fund owned...

Insider Selling: Arcus Biosciences (NYSE:RCUS) CEO Sells 25,744 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CEO Terry Rosen sold 25,744 shares of Arcus Biosciences stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at...

Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 2,113 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CAO Alexander Azoy sold 2,113 shares of the business's stock in a transaction on Wednesday, December 17th. The shares were sold at an average...

Alexander Azoy Sells 2,376 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CAO Alexander Azoy sold 2,376 shares of the business's stock in a transaction on Tuesday, December 16th. The stock was sold at an average price...

Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 4,343 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CAO Alexander Azoy sold 4,343 shares of the company's stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an...

Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) insider Richard Markus sold 4,494 shares of Arcus Biosciences stock in a transaction that occurred on Wednesday, December 17th. The stock was...

Carolyn Tang Sells 7,658 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) General Counsel Carolyn Tang sold 7,658 shares of the business's stock in a transaction dated Tuesday, December 16th. The stock was sold at an...

Robert Goeltz II Sells 6,702 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CFO Robert Goeltz II sold 6,702 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average...

Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) General Counsel Carolyn Tang sold 6,810 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average...

Arcus Biosciences (NYSE:RCUS) President Sells 9,983 Shares

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) President Juan Jaen sold 9,983 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average...

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.13	--	--	N/A
Q3 '25	-$1.31	-$1.27	3.05%	BEAT
Q2 '25	-$1.13	-$1.11	1.85%	BEAT
Q1 '25	-$1.03	-$1.14	-10.57%	MISSED
Q4 '24	-$1.25	-$1.03	17.52%	BEAT

RCUS
Arcus Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RCUS News

RCUSArcus Biosciences Inc